Bupivacaine Lipsome Injectable Suspension
153 adverse event reports submitted to the FDA
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
153
Total Reports
10
Deaths Reported
650.0%
Death Rate
Active Ingredients
Bupivacaine Lipsome Injectable Suspension
Administration Routes
IntralesionalUnknownOphthalmicSubcutaneousIntraspinalIntra-gingivalOral
Species Affected
Dog 90
Unknown 46
Human 8
Cat 6
Horse 2
Chinchilla 1
Most Affected Breeds
Unknown 55
Dog (unknown) 29
Retriever - Labrador 8
Crossbred Canine/dog 7
Pit Bull 6
Shepherd Dog - German 4
Boxer (German Boxer) 4
Mixed (Dog) 4
Cat (unknown) 3
Mastiff 2
Most Reported Reactions
Product problem 37
Vials, Damaged 22
Injection site swelling 13
Injection site infection 13
Injection site seroma 12
Application site serosanguinous discharge 9
Other abnormal test result NOS 9
Injection site serosanguinous discharge 9
Death 8
Injection site bruising 7
Stopper, abnormal 7
Injection site serous discharge 5
Outcome Breakdown
Outcome Unknown
49 (45.8%)
Recovered/Normal
48 (44.9%)
Died
8 (7.5%)
Euthanized
2 (1.9%)
Source: FDA Center for Veterinary Medicine — Adverse Event Reports. Data reflects voluntary submissions and may not represent actual incidence rates.